Partnership with Dubai London Clinics & Hospitals

In brief · summary, not quotable

Oxford BioDynamics Plc has partnered with Dubai London Clinics & Hospitals Group to offer its EpiSwitch PSE prostate cancer test across the UAE, marking its first commercial agreement for this test in the Gulf region. The partnership involves collecting patient blood samples at DLCH facilities for processing at OBD's UK laboratory, with the end-to-end clinical workflow having been successfully validated. Both companies will collaborate on market development and clinician engagement, with test volumes expected to increase over time.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes

Oxford, UK - 13 August 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, announces that it has entered into a partnership agreement with The Dubai London Clinics & Hospitals Group ("DLCH"), one of Dubai's longest-established private healthcare providers. This agreement makes OBD's EpiSwitch PSE prostate cancer test available across DLCH's network of clinics and hospitals across the United Arab Emirates.

Highlights

Agreement to offer OBD's EpiSwitch PSE prostate cancer test across Dubai London Clinics & Hospitals network
End-to-end clinical workflow successfully validated between Dubai and OBD's UK laboratory
First commercial partnership for EpiSwitch PSE in the Gulf region

Under the agreement, patient blood samples will be collected at DLCH facilities and processed at OBD's laboratory in the UK. The end-to-end clinical workflow has been successfully validated between the two organisations.

The Company and DLCH will work together to support adoption across DLCH's clinician network, including local market development and engagement with regional payers. Test volumes are expected to build over time as these activities commence.

DLCH operates a network of five facilities, including the Australian Council on Healthcare Standard International (ACHS)-accredited Dubai London Hospital in Jumeirah, Dubai.

Further details on the partnership will be announced jointly by OBD and DLCH in due course.

Richard Compton, Chief Executive Officer at Oxford Biodynamics, said:

"We're delighted to be partnering with DLCH to make EpiSwitch PSE available across its facilities in the UAE. This is our first commercial partnership for the test in the Gulf region and an important milestone as we continue to expand internationally. We've already successfully validated the workflow between DLCH and our UK laboratory and look forward to working closely with the team to support adoption among clinicians and build awareness of the benefits our test can provide."

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.